Organization: MPM Capital

Neuromed raises US$25M for clinical development

Neuromed Pharmaceuticals has raised an additional US$25 million in a series D financing that brings its cumulative venture capital financing to $74 million. The new capital will be used to advance development of its lead compound for the treatment of chronic pain and its second development program for the treatment of anxiety, epilepsy and cardiovascular…

NeuroMed takes top spot with US$32M financing round

NeuroMed Technologies Inc has scored the largest private biotech financing in Canada this year, raising US$32 million for development of its next-generation chronic pain drugs. Proceeds will be used to move the Vancouver-based company’s lead compound to completion of Phase II clinical trials, and to fund further development of its preclinical pipeline. Investors in the…